Precision medicine study for young children with cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study enrolls newly diagnosed infants with cystic fibrosis to follow them during “precision medicine” care. It may help doctors better understand which treatments and monitoring work best, especially before certain infections develop.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child was recently diagnosed with cystic fibrosis in a classic form
- Your child has had two positive sweat tests and/or specific CFTR gene changes (from Class I to III)
- Your child does not currently have an infection or bacteria called Pseudomonas aeruginosa
- You (the parent/guardian) are able to sign consent to join the study
- The child is covered by the French social security system
- Your household can communicate in French for consent and study participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the natural course of cystic fibrosis in young children (under 6) and healthy babies over time. It aims to understand how the disease changes in the era of modern treatments, which could help improve care and guide future therapies.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This study collects cells from people with cystic fibrosis (CF) caused by rare CFTR gene changes. The goal is to build a cell bank for future research, which may help scientists develop better tests and treatments for rare CF types.
This early study tests an individualized approach (“theratyping”) to match your cystic fibrosis (CF) to the CFTR medicine that may work best for your specific genetic change. It may help find a more tailored treatment plan and see how your body responds, while using medicines that are already approved for some people with CF.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.